Cascade predictive genetic testing is available for many families as a means to identify individuals at risk of long QT syndrome (LQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT), hypertrophic cardiomyopathy (HCM), and arrhythmogenic right ventricular cardiomyopathy (ARVC). The general issue of offering predictive genetic testing to minors has been an area of ethical debate among genetic counselors and other healthcare professionals for many years. An online questionnaire was circulated to four international genetic counseling associations to assess the views of cardiac genetic counselors regarding when to offer predictive genetic testing to children at risk of LQTS, CPVT, HCM, and ARVC. Analysis was both quantitative and qualitative. The study sample comprised 98 respondents. The majority reported that they offer predictive genetic testing before 5 years of age to children at risk of LQTS (83%) and CVPT (75%) and before 10 years of age to children at risk of HCM (66%) or ARVC (70%). Influencing factors included country of practice, clinical setting, and years of experience. The rationale provided for when to offer predictive genetic testing is encompassed by the ethical principles of beneficence, non-maleficence, autonomy, and informed consent. In conclusion, significant practice variation exists among cardiac genetic counselors regarding predictive genetic testing for children at risk of an inherited cardiomyopathy. These variations call for more research in the area to assist with the development of evidence-based guidelines.
Introduction
With advances in the field of cardiac genetics, cascade predictive genetic testing is now available in many families as a means to identify children at risk of an inherited arrhythmia or cardiomyopathy, such as long QT syndrome (LQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT), hypertrophic cardiomyopathy (HCM), and arrhythmogenic right ventricular cardiomyopathy (ARVC). Each condition carries a risk of sudden cardiac arrest which can present at any time between infancy and old age. Arrhythmic events are more common between the preteen years and the early 20s for LQTS and between 7 and 12 years of age for CPVT (Alders and Mannens 2015; Napolitano 2016) . The risk is greatest during adolescence for HCM and adulthood for ARVC (Cirino 2014; McNally 2014) . Variable expression and incomplete penetrance are common for all four conditions and electrocardiographic abnormalities can be concealed for LQTS and CPVT, complicating diagnosis.
Mixed opinions currently exist regarding the optimal age to initiate predictive cardiac genetic testing for children. Early identification and intervention could potentially be lifesaving. Prophylactic beta blocker therapy has been shown to reduce the risk of cardiac events in individuals diagnosed with LQTS or CPVT (Alders and Mannens 2015; Napolitano 2016) . Individuals with LQTS, CPVT, HCM, or ARVC may also be restricted from high-intensity competitive sport, based on an association with life-threatening cardiac arrhythmias (Dunbar et al. 2012; Maron et al. 2004 Maron et al. , 2015 Pelliccia et al. 2005) . The prescription of physical activity restriction is more common for individuals who are phenotype-positive, although it may be considered for some individuals who are phenotype-negative (Christian et al. 2016) . For example, recent studies have shown a positive correlation between intensity and amount of physical activity with severity of disease for individuals at risk of ARVC which may support limiting physical activity in phenotype-negative individuals (James et al. 2013; Kirchhof et al. 2006; Saberniak et al. 2014 ).
On the other hand, testing young children removes their autonomy and their ability to provide informed consent (Hein et al. 2015) . In addition, concerns have been raised regarding positive cardiac genetic test results potentially leading to negative psychological effects, causing overprotection and stigmatization, and resulting in discrimination later in life with regard to insurance and employability (Bonner et al. 2018; Bratt et al. 2012; Geelen et al. 2011; Meulenkamp et al. 2008; Mohammed et al. 2017) .
A consensus statement by the Heart Rhythm Society and the European Heart Rhythm Association recommends that predictive genetic testing be offered as early as infancy for LQTS and CPVT to assist with medical management (Ackerman et al. 2011) . In contrast, for cardiomyopathies, the European Society of Cardiology's position statement and the Australian/New Zealand guideline suggest that predictive genetic testing be deferred until 10 to 12 years of age (Charron et al. 2010; Ingles et al. 2011) . North American guidelines do not specifically address the issue of when predictive genetic testing should be offered for cardiomyopathies (Ackerman et al. 2011; Gollob et al. 2011; Hershberger et al. 2018) . Older guidelines recommend that cardiac screening begin around 10 to 12 years of age whereas the more recently published guidelines by the Heart Failure Society of America suggest at least one cardiac evaluation for children under 5 years of age who have a first-degree relative diagnosed with HCM or ARVC (ACCF/AHA et al. Task Force members et al. 2014; Corrado et al. 2015; Hershberger et al. 2018) .
This study assessed the current practices of cardiac genetic counselors regarding when to offer predictive genetic testing for asymptomatic children at 50% risk of LQTS, CPVT, HCM, or ARVC. The study also describes genetic counselors' rationale for when to offer predictive genetic testing.
Materials and Methods

Data Collection
An online questionnaire was circulated to the Canadian Association of Genetic Counsellors (CAGC), the National Society of Genetics Counselors (NSGC), the Australasian Society of Genetic Counsellors (ASGC), and the Association of Genetic Counsellors and Nurses (AGCN) in the UK between July and October 2016. The questionnaire was developed by the research group based on clinical experience as a validated tool was not available (Supplementary Material). Cardiac genetic counselors were asked to indicate the youngest age at which they felt that predictive genetic testing should be offered to asymptomatic children at 50% risk of LQTS, CPVT, HCM, or ARVC. An assumption was made that genetic counselor's views were consistent with their practice. The following age categories were included: 0-5 years, 6-9 years, 10-15 years, 16-18 years, and > 18 years. These age categories were selected to allow for comparison of the recommended age of predictive genetic testing with published consensus and position statements (before 5 years for LQTS and CPVT and after 10 years of age for HCM and ARVC). If more than one age range was selected, the youngest age category was used. An open-ended question was included to assess the genetic counselor's rationale for choosing the specific age range for predictive genetic testing. Demographic information was also collected.
The survey was created using Survey Monkey Inc. (Palo Alto, CA, USA). An email invitation and reminder with a Web link was circulated to the memberships of the above groups through their respective list servers. The sole inclusion criterion was self-identifying as a cardiac genetic counselor. Submitted surveys were excluded if the respondent was not a practicing genetic counselor or if less than two questions were completed. The survey took approximately 5 to 10 min to complete. Approval was obtained from the University of Alberta Research Ethics Office.
Data Analysis
The proportion of genetic counselors who selected each age range to offer predictive genetic testing is described for each condition and compared to published consensus and positions statements. Chi square analysis, Fisher exact test, and univariate logistic regression were used to assess the relationship between when to offer predictive genetic testing and the independent variables including country of practice; years of experience as a cardiac genetic counselor; clinical setting (Medical Genetics, Cardiology, Multidisciplinary); and respondent's gender. Data on country of practice was grouped to reflect genetic counselors practicing within North American (Canada and USA) and those practicing outside of North America (UK, Australia, and New Zealand) .
The open-ended question was reviewed by two independent coders to identify key themes provided to justify the youngest age to offer predictive genetic testing. Consensus was reached between the coders.
Results
A total of 102 responses were received. Four responses were excluded: three completed only the first question on the survey and one was completed by a genetic counseling student. It is not possible to calculate a response rate as the total number of genetic counselors involved in providing cardiac genetic counseling in all associations is unknown and many counselors are members of multiple associations. The National Society of Genetic Counsellors 2016 Professional Status Survey reported that 152 members provide genetic counseling to cardiac patients, with the majority of these counselors working in the USA and Canada (NSGC 2016) . This would suggest a response rate of roughly 47% (71/152) for North American genetic counselors. Characteristics of the respondents are shown in Table 1 .
Predictive Genetic Testing
The majority of respondents practice in accordance with published guidelines for LQTS (81/98, 83%) and CPVT (73/96, 75%), offering predictive genetic testing to children before 5 years of age. Practice was less consistent with published guidelines with regard to offering testing to children after 10 years of age at risk of HCM (33/98, 34%) and ARVC (29/97, 30%) ( Fig. 1 ). The vast majority (96-99%) reported that they offer testing for all four conditions at some point during childhood (< 18 years of age).
Country of practice was significantly associated with whether respondents offer predictive genetics testing for at-risk children before or after 10 years of age for HCM and ARVC (Fig. 2) . Respondents practicing within North America had 16.6 times the odds (CI 4.97, 59.49, p < 0.001) and 8.97 times the odds (CI 2.90, 28.31, p < 0.001) of offering predictive genetic testing to children before 10 years of age for HCM and ARVC, respectively, compared to genetic counselors practicing outside of North America. Overall, 22% (6/27) of genetic counselors practicing outside of North America offer predictive genetic testing before 10 years of age for HCM and 33% (9/27) offer testing this early for ARVC. Years of experience proved to be significantly associated with offering predictive genetic testing before 5 years of age for LQTS with more experienced cardiac counselors offering testing to children under 5 years (p = 0.02). This same association was not seen for the other cardiac conditions. Whereas, respondents working within Medical Genetics or a Multidisciplinary Clinic were less likely to offer predictive genetic testing prior to 10 years of age for HCM and ARVC compared to those working solely within Cardiology (p = 0.02/p = 0.06, p = 0.008/p = 0.02, respectively) ( Table 2) .
Rationale for when to Offer Predictive Genetic Testing
Eighty-one respondents provided rationale for when to offer predictive genetic testing. The most common theme was natural history of the disease (57%, 46/81) with 13 respondents specifically commenting on age of presentation within a family. This was followed by the opportunity to initiate management (48%, 39/81) and screening (37%, 30/81). Additional themes included lifestyle modification (i.e., physical activity) (20%, 16/81); psychological benefits or harms (17%, 14/81); and autonomy (9%, 7/81). Thirteen respondents (16%) indicated that parents should decide when it is in the Bbest interest^of their child to perform predictive genetic testing and six respondents (7%) specifically referred to following published professional guidelines. Many responses included a combination of reasoning. Table 3 describes the breakdown of rationale for when to offer testing based on country of practice.
The following are examples of statements provided to justify offering predictive genetic testing to children at an earlier age (i.e., < 5 years of age):
& BPsychosocially, we prefer to test before kids start participating in organized sports, as many of the conditions have exercise restrictions. Some of our families find it easier to steer them away from certain athletics from a young age if they're positive, rather than let them play and start to really love a sport and want to play competitively and then have that taken away from them when they test positive at a later age.^USA & BScreening is more expensive and anxiety provoking than genetic testing for most families 
Discussion
The identification of a pathogenic variant for an inherited arrhythmia or cardiomyopathy such as LQTS, CPVT, HCM, and ARVC permits cascade genetic testing within a family to identify at-risk individuals. Families with young children may be provided with two options: perform predictive genetic testing to clarify genetic status and appropriate management or perform regular cardiac screening and consider predictive genetic testing when the child is older (i.e., > 10 years of age).
This study aimed to summarize current practices and the justification for those practices among an international group of genetic counselors.
When to Offer Predictive Genetic Testing
This study found that 83 and 76% of respondents would offer predictive genetic testing before 5 years of age for children at risk of LQTS or CPVT. One might have expected an even greater number to offer predictive genetic testing at this young age based on the association with sudden infant death syndrome (Napolitano 2016) . Genetic counselors' years of experience was associated with offering predictive genetic testing at an earlier age for LQTS. This may reflect the impact of years of experience on clinical knowledge or exposure to the variable onset of this condition. It may also reflect changing personal and/or family circumstances and values. It is unclear why this finding was only seen with regard to LQTS. We also found that genetic counselors practicing within Cardiology were more likely to offer testing before 10 years of age for HCM and ARVC compared to those working within Medical Genetics or a Multidisciplinary Clinic. This may be explained by Cardiology genetic counselors being more specialized and having a greater appreciation for the phenotypic variability of these conditions. It may also be due to genetic counselors being influenced by cardiologists aiming to eliminate unnecessary cardiac screening for children.
Respondents were less likely to offer predictive genetic testing before 5 years for HCM and ARVC compared to LQTS and CPVT, although the vast majority offer testing at some point in childhood. These findings likely reflect an older average phenotypic age of onset for these conditions and are consistent with professional guidelines (Alders and Mannens 2015; Charron et al. 2010; Cirino 2014; Ingles et al. 2011; Iyer and Chin 2013; Napolitano 2016) .
Country of practice significantly influenced whether or not respondents followed published guidelines with regard to HCM and ARVC. Respondents practicing in North America more commonly offer testing earlier in childhood compared to respondents practicing outside of North America. Although North American cardiac genetic testing guidelines do not specifically address the issue of predictive genetic testing in minors for cardiomyopathies, practice may be influenced by more general position statements such as the American Society of Human Genetics which emphasizes the importance of parental involvement with regard to predictive genetic testing in minors in the presence of clinical uncertainty (Botkin et al. 2015) .
A policy statement published by the American College of Medical Genetics on reporting of secondary findings causes further re-evaluation of genetic testing in children (Kalia et al. 2017). The identification of a cardiac pathogenic variant, in this context, takes a bottom up approach and allows for the testing and/or screening of relatives who would have otherwise not been aware of the condition. Wynn et al. found that a group of adults did not show increased anxiety, depression, or health worry following the finding of a secondary genetic finding (Wynn et al. 2018) . They concede that Bthe experience of receiving secondary results may differ from the results of focused clinical testing because in the latter case patients are likely to have greater familiarity with the condition, have deliberately sought specific genetic information, and have the opportunity to prepare psychologically for the findings.^It should be noted that this study evaluated the perspective of adults and the impact of secondary findings for children remains unclear. Regardless, with an increasing number of cardiac secondary findings being reported from whole exome sequencing, North American genetic counselors may be becoming more relaxed in their views around predictive genetic testing in minors (Kalia et al. 2017) . Debate remains among European, Australian, and Canadian professional groups regarding the reporting of secondary findings and a more targeted approach to testing is currently recommended (Boycott et al. 2015; Hehir-Kwa et al. 2015; RCPA 2015) .
Finally, medical malpractice rates have historically been higher in North America compared to Australia and the UK (Danzon 1990 ). The North American approach is consistent with a shared decision-making model which may be influenced by concerns of medical liability (Monico et al. 2008) .
In contrast, the European and Australia/New Zealand guidelines suggest deferring predictive genetic testing until after 10 years of age for children at risk of a cardiomyopathy (Charron et al. 2010; Ingles et al. 2011) . In addition, more general statements by the European Society of Human Genetics and Human Genetics Society of Australasia specifically emphasize that predictive genetic testing should only be offered to children at the age at which a condition is expected to present and when there is medical benefit (Borry et al. 2006; HGSA 2017) . In the absence of specific guidelines in North America, some American and Canadian genetic counselors may also be drawn to these European practice recommendations.
Overall, variability in practice was observed among genetic counselors practicing in countries with and without clear published guidelines. Variability in professional guidelines highlight that they were created based on expert opinion rather than empiric evidence. An assessment of the impact of age of predictive genetic testing on the modified natural history of these conditions and quality of life is needed for these populations.
In general, predictive genetic testing is not common during childhood and as a result, there are limited appropriate conditions for comparison. A few inherited cancer syndromes including familial adenomatous polyposis (FAP) and Li-Fraumeni syndrome can present during adolescence and as such, predictive genetic testing may be considered. Published guidelines recommend predictive genetic testing for childhood cancer syndromes when a child reaches the age at which the cancer predominately presents and screening is generally initiated (ASCO 2003) . Although there are inherent differences with regard to penetrance and invasiveness of screening methods for childhood cancer syndromes compared to inherited arrhythmias and cardiomyopathies, a study by Douma et al. reported that the majority of parents feel that the most suitable time to perform predictive genetic testing for children at risk for FAP is after 12 years of age (Douma et al. 2010) . In contrast, Gjone et al. noted a trend towards better health and psychosocial functioning for children tested for FAP at birth as part of a research study compared to those tested at an older age (Gjone et al. 2011) . In addition, 11 of 12 adolescents and young adults who underwent predictive genetic testing for Li-Fraumeni syndrome during childhood did not feel that parents should delay testing until a child is old enough to take part in the decision-making process (Alderfer et al. 2017) . Rationale for when to Offer Predictive Genetic Testing
Rationale for when to offer predictive genetic testing included the natural history of the disease, clarification of who requires ongoing cardiac screening, implementation of treatment, lifestyle modifications, psychological benefits and harms, the child's autonomy, parents' autonomy, and following published guidelines. These factors are considered further in the context of the ethical principles of beneficence, non-maleficence, autonomy and informed consent.
Beneficence
With respect to when to offer predictive genetic testing for LQTS, CPVT, HCM, or ARVC, respondents in this study reported the following potential benefits: cardiac screening, beta blocker therapy, lifestyle modification, and reduced anxiety. Respondent's rationale was also influenced by their interpretation of the natural history of the conditions.
Cardiac screening Genetic testing has the ability to clarify who requires ongoing cardiac screening. This eliminates unnecessary cardiac assessments for children who do not carry the familial pathogenic variant resulting in decreased burden for the family and the healthcare system.
Beta blocker therapy Prophylactic beta blocker therapy has been shown to reduce the risk of cardiac events for individuals diagnosed with LQTS and CPVT (Goldenberg et al. 2008; Koponen et al. 2015; Postma et al. 2005; Villain et al. 2004) . As a result, professional guidelines recommend beta blocker therapy even for genotype positive, phenotype negative individuals (Ackerman et al. 2011; Napolitano 2016) .
Lifestyle modification Historically, professional guidelines have recommended that phenotype positive individuals with LQTS, CPVT, HCM, or ARVC avoid high-intensity competitive sport (Maron et al. 2005; Pelliccia et al. 2005) . Clarification of genetic status at a young age may lead parents to guide their child towards lower intensity activities. This averts the need for the child to be disqualified from sport at a point when their self-identity and social relationships are strongly linked to these activities.
Reduce anxiety Genetic testing performed early in childhood has the potential to significantly reduce anxiety for the families of children found not to carry a familial pathogenic variant. This is supported by a prospective assessment of children who tested negative for a familial FAP variant who were found to have reduced anxiety, worry, and distress following testing (Michie et al. 2001) .
Natural history Consideration of the natural history of each cardiac condition could lead one to offer predictive genetic testing earlier, if the youngest possible age of onset is considered, or later if the more common age of onset is considered.
Non-maleficence
Potential harms relating to when to offer predictive genetic testing for LQTS, CPVT, HCM, and ARVC included unnecessary restriction of physical activity and anxiety.
Unnecessary physical activity restriction Although physical activity restriction based on genetic status may be seen as a benefit to a child, this could also be considered a potential harm. Participation in sports has many physical, psychological, and social benefits (DiLorenzo et al. 1999; Helmrich et al. 1991; Mammen and Faulkner 2013; Nocon et al. 2008) .
Recent guidelines suggest that participation in competitive sport may be acceptable for individuals diagnosed with LQTS following a period of stability on beta blocker therapy . In addition, the penetrance of HCM is variable and more commonly presents during adulthood.
Testing a child at a young age may eliminate their chance to benefit from sport participation unnecessarily.
Increase anxiety Predictive genetic testing may increase psychological distress for children and their parents when a pathogenic variant is identified (Bratt et al. 2011; Geelen et al. 2011) . Two systematic reviews looking at the impact of predictive genetic testing for a variety of genetic conditions, for children and young adults, did not find a negative effect on emotional state, self-perception, or social well-being although research in the area was reported as limited (Wade et al. 2010; Wakefield et al. 2016) . Whereas qualitative research in cardiac genetics has identified some potential concerns (Bonner et al. 2018; Bratt et al. 2011 Bratt et al. , 2012 Geelen et al. 2011; Meulenkamp et al. 2008 (Bonner et al. 2018 ). This highlights the importance of an in-depth conversion with families around these key issues to reduce the psychological impact of testing. Finally, parents have raised concerns that predictive genetic testing at a young age may also lead to additional years of stigmatization and overprotection (Geelen et al. 2011) . The validity of these concerns have yet to be investigated.
Autonomy/Informed Consent
Autonomy describes the ability of an individual to make informed choices about their own health. Young children lack the capacity to comprehend the potential benefits and harms of predictive genetic testing. The age at which a child develops this ability is likely variable. Hein et al. suggest that children under 10 years of age are unlikely to have the competence required for involvement in the consenting process whereas children over 12 years of age are likely to be competent (Hein et al. 2015) . The European and Australian/New Zealand guidelines suggest consideration of predictive genetic testing for cardiomyopathies between 10 and 12 years of age (Charron et al. 2010; Ingles et al. 2011) . Thirteen responses suggested that the ultimate decision regarding when to perform predictive genetic testing should be left to the discretion of the family. Geelen et al. effectively illustrated that families can weigh the potential benefits and harms differently and come to opposite conclusions (Geelen et al. 2011) . Parents have a greater understanding of the child and family situation and are likely in a better position to appreciate the true impact of predictive genetic testing. Parental anxiety may also be considered and a negative genetic result may provide significant reassurance for the parents.
Study Limitations
This study reports the opinions of genetic counselors practicing in the field of cardiac genetics. We were unable to determine an accurate response rate and it is therefore difficult to generalize these results to all cardiac genetic counselors. We were also unable to consistently link the rationale provided by respondents to the specific conditions based on the structure of the survey.
Conclusions
Variation in practice was observed among an international group of genetic counselors regarding when to offer predictive genetic testing for children at risk of an inherited cardiomyopathy. Country of practice and clinical setting were significantly associated with when respondents offer predictive genetic testing for HCM and ARVC which likely reflects published guidelines. In addition, years of experience impacted the age at testing in LQTS. This study highlights the complex issues surrounding predictive genetic testing in minors and the importance of genetic counseling to assist families' in reaching a personalize decision around testing. It also illustrates the impact of evolving views in genetics and supports the need for more research in the area to assist with the development of congruent and evidence-based guidelines grounded on ethical principles, with recognition of the parental role in decision-making.
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